I have been struggling now with a condition for about eight years. I have recently been interested in learning about PPAR as I think it maybe driving my condition. Or rather, its signaling may be off. Hoping someone here can let me bounce some ideas off them or maybe recommend a place that may also have people weighing in on this subject. Thanks.
#1
Posted 14 December 2016 - 10:14 PM
#2
Posted 15 December 2016 - 01:05 AM
I've read about PPARs a fair bit.
One interesting review paper is:
One interesting video is:
NIH Cast - PPARs Treatment and Disease Prevention
#3
Posted 15 December 2016 - 04:28 AM
Are you familiar at all with the bile related receptors and their influence like LXR, or FXR?
#4
Posted 15 December 2016 - 07:18 PM
LXR is a nuclear receptor, but not a PPAR. I have a decent chunk of notes on LXR and related matters. I think I watched some presentations from Dr. Thomas Dayspring on www.lecturepad.org or on youtube. You can search for his presentations on lipidology and LXR/RXR receptors. He's quite good.
#5
Posted 15 December 2016 - 07:30 PM
Yes, I basically think that I have an issue with these receptors and their influence on PPAR signaling.
#6
Posted 15 December 2016 - 08:25 PM
Yes, I basically think that I have an issue with these receptors and their influence on PPAR signaling.
I've no idea what to make of that without any medical test results or data. You would obviously need someone like a clinical lipidologist to evaluate it.
#7
Posted 15 December 2016 - 11:06 PM
OK, let me ask you this. What do you think acute ethanol exposure would do to PPAR? I am wondering if its anti-inflammatory effects may enhance PPAR-a.
#8
Posted 16 December 2016 - 08:50 PM
I'm not qualified to offer an opinion on the interaction of ethanol and ppar-alpha. AFAIK, PPARs are involved in fatty acid breakdown and fatty acid metabolism in general (storage, etc.).
I suppose if a human being ingests ethanol, it converts to triglycerides and there is some kind of PPAR deficiency it will result in a poor handling of the triglycerides. But it's hard for me to say what if anything that will entail. There would have to be some kind of physiological evidence in the form of hepatic steatosis (fatty liver disease).
#9
Posted 28 December 2016 - 03:15 AM
Do you know what the relationship is between ppar a/y with ppar delta? I have gathered that Ppar delta may inhibit their actions.
I'm not qualified to offer an opinion on the interaction of ethanol and ppar-alpha. AFAIK, PPARs are involved in fatty acid breakdown and fatty acid metabolism in general (storage, etc.).
I suppose if a human being ingests ethanol, it converts to triglycerides and there is some kind of PPAR deficiency it will result in a poor handling of the triglycerides. But it's hard for me to say what if anything that will entail. There would have to be some kind of physiological evidence in the form of hepatic steatosis (fatty liver disease).
#10
Posted 28 December 2016 - 03:43 AM
Sent from my XT1575 using Tapatalk
#11
Posted 01 January 2017 - 09:13 PM
In your reading did you come across any good agents that increase ppar-a proliferation without increasing ppar-y? Or any agents that block nf-kappa-b from binding with ppar alpha DNA signaling?
Read the material provided
Sent from my XT1575 using Tapatalk
#12
Posted 02 January 2017 - 12:22 AM
We describe two novel, potent oxybenzylglycine PPARalpha-selective agonists, BMS-687453 [N-[[3-[[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]phenyl]methyl]-N-(methoxycarbonyl)-glycine] and BMS-711939 N-[[5-[[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]-2-fluorophenyl]methyl]-N-(methoxycarbonyl)-glycine], that robustly increase apolipoprotein (Apo) A1 and high-density lipoprotein cholesterol in human ApoA1 transgenic mice and lower low-density lipoprotein-cholesterol and triglycerides in fat-fed hamsters.
Mukherjee R, e. (2008). Novel peroxisome proliferator-activated receptor alpha agonists lower low-density lipoprotein and triglycerides, raise high-density lipoprotein, an... - PubMed - NCBI . Ncbi.nlm.nih.gov. Retrieved 2 January 2017, from https://www.ncbi.nlm...pubmed/18799592
#13
Posted 02 January 2017 - 01:36 AM
You feel LXR agonism would be a superior route?
#14
Posted 02 January 2017 - 02:35 AM
You feel LXR agonism would be a superior route?
Impossible for me to say. 1) I'm not a doctor and I've still got a long way before I really understand this area. 2) I don't even know what kind of metabolic issue you are talking about. I only provided these links and information as an overview of PPARs. I'm not even sure what you are trying to address other than to under PPARs.
Some kind of fibrate is typically the answer for a pharmacologic activation of PPARs. But fish oil (PUFAs), niacin other approaches are possible. It just depends on what is going on and it's impossible for me to say with any kind of certitude.
#15
Posted 15 January 2017 - 03:07 PM
Condition/problem?
Hypotheses?
Main objective / current target or method to correct it?
What is the problem and what do you want to do about it?
I am in the same situation.
Disease occurred 3 years ago.
Still struggling and testing to correct it.
PPAR's may be involved. Especially PPAR gamma.
Other receptors of interest:
RAR. CAR. PXR. AHR.
#16
Posted 15 January 2017 - 03:11 PM
Try to increase it through sustainable means.
Fasting. Exercise. Low carb and possibly calorie diet.
Minimize insulin.
But what is the problem?
Looking only at mechanisms, we can't assist you.
#17
Posted 19 January 2017 - 09:35 PM
Interesting writeup here https://www.ncbi.nlm.../table/tbl0005/
But it deals mostly with PPAR-gamma agonists.
PPAR-delta seems to improve mitochondrial number, and may reduce weight gain. The effect on endurance is similar to exercise. PPARdelta agonists such as AiCAR have been banned in sport for this reason. Micardis is an angiotensin reuptake inhibitor that also activates PPAR-delta. It causes fewer respiratory problems than other angiotensin reuptake inhibitors. But can still cause cough, and possibly lung cancer though this is debatable.
I believe PPAR-alpha agonists such as fibrates tend to induce weight gain, whereas PPAR-gamma agonists do not. Both tend to reduce insulin resistance.
Luteolin and resveratrol are two substances that activate both of these PPARs.
I hope you find what you need.
i n
#18
Posted 20 January 2017 - 04:27 AM
You got that mixed up. Fibrates and PPAR-alpha agonists tend to cause weight loss. PPAR-gamma agonists tend to cause not just weight gain, but adipogenesis as well.PPAR-delta seems to improve mitochondrial number, and may reduce weight gain. The effect on endurance is similar to exercise. PPARdelta agonists such as AiCAR have been banned in sport for this reason. Micardis is an angiotensin reuptake inhibitor that also activates PPAR-delta. It causes fewer respiratory problems than other angiotensin reuptake inhibitors. But can still cause cough, and possibly lung cancer though this is debatable.
I believe PPAR-alpha agonists such as fibrates tend to induce weight gain, whereas PPAR-gamma agonists do not. Both tend to reduce insulin resistance.
Also tagged with one or more of these keywords: ppar
Science & Health →
Supplements →
Resveratrol →
Resveratrol, PPARδ/PPARγ agonists, AICAR etc.Started by maxwatt , 04 Mar 2013 resveratrol, aicar, ppar and 3 more... |
|
|
1 user(s) are reading this topic
0 members, 1 guests, 0 anonymous users